Identifying novel gene rearrangements is an important process in drug discovery and also the key to good drug design. Serving as a leader and supplier in the biochemical market, Creative Biolabs has developed an original microfluidic chip-augmented gene rearrangement screening platform for offering one-stop microfluidic solutions to drug development. We believe, with our team of experts and most up-to-date facilities, we could help you to tailor the best microfluidic chips to suit the best to your projects.
Gene rearrangement is the variation that a kind of gene abnormality involving a change in the gene copy number, recombination of gene fragment, as well as an alternation of gene expression profiling. In general, it is caused by the breaking of the DNA double helix, and then the broken ends are reconnected to produce a new sequence of genes, which is different from the sequence before the chromosome was broken. Nowadays, gene rearrangements can be divided into two categories: incidental gene rearrangement and programmed gene rearrangement. The incidental gene rearrangement occurs during gene replication, gene repair, or gene recombination. The results have indicated that these gene rearrangements are often unpredictable, but most of them are harmful to health. However, programmed gene rearrangements have been considered to be a natural developmental process of an organism and its offspring. Nearly all results of these rearrangements can be detected by using certain enzymes.
Fig.1 Gene rearrangements, common gene rearrangements in cancer cells. (Alshalalfa, 2012)
Currently, the identification of gene rearrangements in various malignant tumors is important for improving clinical outcomes. Pilot studies have demonstrated that next-generation sequencing (NGS) technology is a powerful tool for screening gene rearrangements. Moreover, recent studies have shown that recurrent gene aberrations are associated with various cancer progressions, such as leukemias and carcinomas. For instance, recent studies have shown that the specificity of ALK/KMT2A rearrangement has been analyzed on a battery of rearranged cancers by NGS assays. The data have indicated that several ALK/KMT2A rearrangements with a common noncanonical intron 16 breakpoints might affect the response to targeted drugs, which providing meaningful data for tumor molecular testing.
In recent years, the microfluidic chip-based approach has been proved its significant role in molecular profiling, disease prevention, and treatment. As a result, Creative Biolabs offers a full range of customized microfluidic chip-based gene rearrangement screening services to bring further progress in the drug discovery field. Our microfluidic chip-augmented gene rearrangements platform is ideal for controlling the expression of many genes and identifying gene diversity in different species. Till now, we have successfully detected several rearrangements of ALK/ROS1 in non-small cell lung cancer models. The copy numbers of ALK/ROS1 rearrangements could be used for evaluating treatment responses and disease progression.
Creative Biolabs is specialized in designing and performing high-quality custom microfluidic chip-based gene rearrangement detection assays, with different formats, endpoints, parameters, to satisfy any specific requirement at a most competitive price. For more detailed information, please feel free to contact us or directly sent us an inquiry.
For Research Use Only. Not For Clinical Use.